The stock's rise snapped a three-day losing streak.

We came across a bullish thesis on Edwards Lifesciences Corporation (EW) on Substack by Natan. In this article, we will ...

Edwards Lifesciences Corp. closed 24.63% below its 52-week high of $96.12, which the company reached on March 28th.

Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared ...

Spire Wealth Management lessened its holdings in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 23.1% during the 4th quarter, according to its most recent filing with the Securities & Exchange ...

In the latest quarter, 11 analysts provided ratings for Edwards Lifesciences EW, showcasing a mix of bullish and bearish ...

Fintel reports that on January 30, 2025, Stifel upgraded their outlook for Edwards Lifesciences (NYSE:EW) from Hold to Buy.

Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...

Learn more about whether Edwards Lifesciences Corporation or Stryker Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Edwards Lifesciences Co. (NYSE:EW – Get Free Report) has been given a consensus rating of “Hold” by the twenty-six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...